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Abstract
Background: Considering the increasing incidence of coronary artery stenosis and its related com-
plications, the importance of its etiology and inconsistent reports we aimed to determine the relation-
ship between oxysterol, serum levels and severity of coronary atherosclerosis and effect of statins on
oxysterol.
Methods: A total of 85 patients referred to Taleghani Hospital, Tehran, Iran during 2011-2012 with
coronary artery stenosis more than 75%, as determined by angiography, participated in the current
study. Their demographic information and history of smoking and taking atorvastatin was carefully
recorded. Two milliliters of venous blood was obtained from each patient. The serum oxysterol level
of samples was measured using the enzyme-linked immunosorbent assay (ELISA) method. Statisti-
cal analysis was performed using SPSS v.19.
Results: Eighty five patients completed the study. Mean age of patients was 64.4 years; 51 (60%)
were male; 55 (68%) had acute coronary syndrome and 30 (32%) had chronic stable angina.
Mean±SD of plasma level of oxysterol was 24.8±0.2 pmol/ml. The normal range of oxysterol level
was 13pmol/ml. Mean±SD of plasma oxysterol level in patients under statin therapy was 24.4±2.1
pmol/ml. In patients without receiving statins, plasma oxysterol level was 26.38±1.6pmol/ml.
Conclusion: Findings of the present study indicated significant correlation between serum oxyster-
ol and severity of coronary artery stenosis. It also demonstrated that receiving atorvastatin is associ-
ated with significant reduction of plasma oxysterol level.
Keywords: Coronary stenosis, Atorvastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, An-
ticholesteremic agents.
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Introduction
Nowadays, cardiovascular diseases are
amongst the major causes of mortality and
morbidity worldwide. In Iran, like other
parts of the world, studies demonstrate that
death toll related to cardiovascular compli-
cations is high (1). According to the reports
by the Iranian Ministry of Health 39.3% of
the deaths in 2005 were due to cardiovascu-
lar diseases. Atherosclerosis, a multifacto-
rial disorder, is one of the major causes of
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stroke and myocardial infarction (2). Sev-
eral causes have been described to be asso-
ciated with the increased risk of acquiring
atherosclerosis. These include high fat di-
ets, hypertension, genetic risk factors, and
using some medications such as anticon-
vulsants (3-6). It has long been believed
that cholesterol level is responsible for de-
veloping atherosclerosis, but currently re-
searchers identified oxidized fats to be ma-
jor contributors of atherogenesis (7). Plas-
ma oxysterols are indicator of lipid oxida-
tive stress and major oxidized bioactive li-
pids, produced during low density lipopro-
tein (LDL) oxidation. Their coalescence in
blood vessels causes cytotoxicity, apopto-
sis, monocyte differentiation and formation
of cell foam and consequently damage and
malfunction of vascular endothelium (8, 9).
They appear to be implicated in the activa-
tion of mitochondrial pathway of apoptosis
and inflammatory and immunological
pathways (10-12). Elevation of the plasma
level of oxysterols has been observed in the
patients with atherosclerosis and directly
correlates with the advancement of athero-
sclerosis in affected areas (9, 13). In 2009
Poli et al. (14) defined six steps for the ath-
erosclerotic effects of oxysterols: 1) endo-
thelial cell malfunction, 2) increase of cel-
lular adherence and secretion of chemicals
which attract the monocytes to the endothe-
lium, 3) Production of foam cells, 4) Over-
production of extracellular matrix compo-
nents and increasing the interaction be-
tween cells and macrophages, 5) Inflamma-
tion and formation of fibrotic cup and 6)
Cellular apoptosis. Studies by Liu et al. and
Rosklint et al. demonstrated that 25-
hydroxycholesterol induce the production
of interleukin-18 and interleukin-1β by
macrophages and contribute to the inflam-
mation and sclerogenesis in the arteries (15,
16).
In 2007, Arca et al. showed that oxyster-
ols are present in hyperlipidemic patients in
high levels (17). In 2008, Szuchman et al.
demonstrated that oxysterols are highly el-
evated in the serum of patients with diabe-
tes and hypercholesterolemia when com-
pared to control groups (18).
It appears that oxysterol and its isomers
are important atherogenic risk factors due
to their high cytotoxicity. In the current re-
search we studied the level of plasma oxys-
terols in patients with severe coronary ar-




Fifty eight patients referred to the
Taleghani Hospital were studied in this
cross-sectional study. Patients included
those suffering from stable angina or coro-
nary artery stenosis, as determined by angi-
ography and were under treatment. Patients
with coronary artery stenosis were referred
to the emergency ward and admitted to the
CCU for acute coronary syndrome; this
group was also examined by angiography.
Patients who agreed to participate in the
study signed the informed consent form.
Study protocol was approved by the Ethics
Committee of the Shahid Beheshti Univer-
sity of Medical Sciences. Study was per-
formed in compliance with the ethical
guideline of the Helsinki Declaration for
medical research involving human subjects.
Sample collection and 25-oxysterol level
measurement
Two milliliters of blood was obtained
from arterial sheath from patients being ex-
amined by angiography and two milliliters
of venous blood was obtained from those
who had been examined previously. More
than 75% of patients were having coronary
artery stenosis. Blood samples were trans-
ferred to the laboratory at endocrinology
and metabolism research center at
Taleghani Hospital. Plasma was separated
by centrifugation and stored at -20°C for
subsequent analyses.
Level of 25-oxysterol was measured by
the enzyme-linked immunosorbent assay
(ELISA) method (CUSABIOTECH, Wu-
han, China). These patients were divided
into two groups, one were receiving statins
at the time of study and one not receiving
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them. The relationship between receiving
the drugs and taking these medications
were investigated.
Statistical analysis
As the distribution of the data was normal
(based on Kolmogorov- Smirnov test), the
quantitative data were presented as mean ±
SD and charts. Student’s t-test was used to
compare the means of two groups and one
sample t-test was used for the comparison
of the means of numerical data from popu-
lation with the expected value of the nor-
mal population. For analysis of qualitative
data, Chi-square and Fisher’s exact tests
were used. P-values less than 0.05 were
considered as significant. All statistical
analyses were performed using SPSS v.19.
Results
In the current study, 85 patients suffering
from severe coronary artery stenosis were
included. Fifty one males (60%) and 34
females (40%) were studied. Mean age of
the subjects was 64.4 years (ranging from
40 to 87 years). About 58 (68%) patients
were suffering from acute angina pectoris
and 27 (32%) from chronic angina pectoris.
Forty two (49.4%) patients were smokers
and 3 (3.5%) had the history of stroke. Six-
ty six patients (87%) were taking atorvas-
tatin.
In the current study patients’ oxysterol
level ranged from 19.37 to 29.8pmol/mol.
Mean±SD of 25-hydroxy cholesterol level
in 85 patients was 24.8±0.2.
No significant correlation between plas-
ma oxysterols and smoking or history of
stroke was observed (p>0.05), while taking
atorvastatin was significantly correlated
with plasma oxysterol levels (p<0.001; Ta-
ble 1). Patients having history of receiving
atorvastatin, but not taking medication in
the study time, had significantly lower
plasma oxysterol levels (p<0.05; Table 2).
Mean±SD level of the plasma oxysterol
in patients was 24.8±0.2pmol/mL. This
amount is significantly higher than that of
the normal population which is estimated to
be about 13.1pmol/mL. Interestingly, when
they were assigned in quartiles, the mean
level of first quartile (22.2pmol/ml) is sig-
nificantly higher than the mean of the nor-
mal population (13.1pmol/ml). Mean level
of oxysterol was significantly lower in pa-
tients receiving atorvastatin (p<0.05).
Discussion
Studying the molecular changes during
atherosclerosis has always been important.
In the current research we studied the
plasma level of oxysterols, specifically 25-
hydroxysterol as important derivatives of
cholesterol metabolism, and its relationship
with consumption of atorvastatin for the
first time in Iranian population. Our re-
Table 1. Correlation between plasma oxysterol level with smoking, stroke and atorvastatin consumption
n % Pearson correlation p
Smoking 42 49.4 0.134 0.243
Stroke 3 3.5 0.188 0.930
Atorvastatin consumption 66 78 0.377 <0.001
Table 2. Mean plasma oxysterol level in patients according to atorvastatin consumption




Table 3. Distribution of plasma oxysterol in patients; SD: standard deviation
Frequency Mean Minimum Maximum
First quartile 24 22.22 19.37 25.33
Second quartile 21 24.30 23.59 24.48
Third quartile 18 25.51 25.08 26.08
Fourth quartile 22 27.49 26.33 29.8
Total 85 24.79 19.37 29.8
Oxysterol in coronary stenosis
4 MJIRI, Vol. 29.192. 14 March 2015http://mjiri.iums.ac.ir
search demonstrated that patients with
more than 75% stenosis of coronary artery
had higher level of plasma oxysterol. Cut-
off for normal level of oxysterol in our
population was 13pmol/ml (19, 20). In our
study, all patients with 75% coronary artery
stenosis had plasma oxysterol levels higher
than 13pmol/mL. Mean level of hydroxys-
terol in 85 patients was 24.8±0.2pmol/mL.
Low standard deviation proves high sensi-
tivity of our measurements. In the study
sample, minimum level of oxysterol was
19.37pmol/mL, and the maximum observed
level was 29.84pmol/mL. These are signifi-
cantly higher than normal amounts.
Kummerow et al. reported higher level of
oxysterols in the plasma from coronary ar-
tery bypass grafting (CABG) patients com-
pared to healthy age- and sex-matched con-
trols. According to their study the concen-
tration of sphingomyelin in the arterial cell
membrane was directly correlated with the
level of oxysterol in the plasma of patients
suffering from severe atherosclerosis. This
is expected to increase calcium influx re-
quired for producing the calcified type VII
lesions in the coronary arteries (21). In
2008, a study by Endo et al. revealed that
increasing the concentration of 7-
ketosterols are associated with coronary
risk factors in diabetic patients. They
demonstrated that oxysterols are amongst
the major causes of oxidation of low densi-
ty lipoproteins (LDLs) and are implicated
in the atherosclerosis process and, hence,
development of cardiovascular diseases
(22).
Findings of the current research are in
compliance with Hodis (23), Zeiden (24)
and Colles (25). Investigations by Hodis in
1991 and Zeiden in the same year in coro-
nary artery patients revealed the role of
oxysterols in degenerative diseases (23,
24).
Yasunobu et al. in 2001 demonstrated
that coronary atherosclerosis is a reflection
of oxysterols and the presence of auto-
antibodies against LDL. Research by
Yasunobu verified the relationship between
oxysterols and coronary stenosis (20). Sa-
lonen et al. confirmed the relationship be-
tween oxysterols and the increase of carotid
wall thickness (26). Results of the current
study, replicate the results from these stud-
ies.
Another study by Qi Zhou et al. in 2000
showed that oxysterol level was higher in
patients with more than 80% coronary ste-
nosis (27).
Marcello Arca et al reported that the level
of oxysterol in familial combined hyper-
lipidemic (FCHL) patients decreases with
the use of anti-hyperlipidemic drugs (28).
According to the data from current study
using statins significantly reduce the level
of plasma oxysterols. Level of oxysterol in
patients receiving atorvastatin was signifi-
cantly lower than patients not using it
(24.4pmol/mL vs. 26.3pmol/mL; p<0.001).
Studies by Rikitake et al. and Sumi et al.
demonstrated that Fluvastatin, another
member of statin family, reduce the pro-
duction of oxidizing radicals (29, 30). In
the study by Giroux et al. it was demon-
strated that simvastatin reduce the produc-
tion of superoxide anions in a dose depend-
ent manner (31).
In a study by Vasanahari et al. it was
demonstrated that treatment with statins
reduces the level of oxysterols in patients
by 24% when compared to control untreat-
ed group (32). In the current study treat-
ment by atorvastatin reduced the plasma
oxysterols level from 26.4±1.6pmol/mL to
24.4±2.1pmol/mL (p=0.001).
In this study mean level of oxysterol was
24.8±2.17pmol/mL which is significantly
more than the normal population’s mean
(23.1pmol/mL). Interestingly, when the
samples were divided into quartiles, the
mean plasma level of oxysterols in the first
quartile (22.2pmol/mL) was significantly
higher than population mean. Among the
variables studied in the current study like
CVA, smoking and receiving atorvastatin,
oxysterol level was significantly reduced in
those receiving atorvastatin. Contradictory
results were achieved by Greet van Poppel
et al. in 1997 demonstrating no relationship
between plasma oxysterol levels with the
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risk of developing atherosclerosis (33).
Although some risk factors did not show
significant differences between two groups,
clinical significance must be kept in mind
in the interpretation of the results as an im-
portant factor. Patients with acute angina
pectoris were having higher levels of oxys-
terols compared with patients with stable
angina pectoris (25pmol/mL vs.
24.2pmol/mL, respectively) but the differ-
ence was not statistically significant
(p=0.231).
Our study provided insight into the in-
volvement of plasma oxysterols in the risk
of developing coronary stenosis and the
potential of atorvastatin for reducing plas-
ma oxysterol level. Considering the exper-
imental evidence regarding the adverse ef-
fects of oxysterols on endothelial cells in in
vitro studies, results appear sound. Howev-
er, due to some limitations due to study de-
sign, lack of controls and long term follow-
up, our data could not be regarded as con-
clusive and further controlled trials are re-
quired for proving the findings.
Conclusion
In sum, the results showed that the level
of plasma oxysterols is directly correlated
with the advancement of coronary stenosis
and its stage. Dramatic elevation of its level
is predictive of severe stenosis. It appears
that treatment with atorvastatin reduces the
level of plasma oxysterols and the risk of
stenosis. However, due to some limitations
in the current study conducting controlled
trials with larger sample sizes to prove this
effect of atorvastatin is recommended.
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